BUZZ-U.S. STOCKS ON THE MOVE-Pure Cycle, Tesla, Five9 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 fell from record highs on Thursday, weighed by megacap stocks, as investors favored small-caps after a softer-than-expected inflation reading bolstered hopes that the U.S.

BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, Crypto stocks, Solar stocks Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes struggled for direction on Thursday as investors favored rate-sensitive small-cap stocks over expensive megacaps after a softer-than-expected inflation reading bolstered hopes for monetary policy easing in September.

BUZZ-U.S. STOCKS ON THE MOVE-Alcoa, WD-40, Broadcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street futures turned positive on Thursday after data showed inflation eased in June, boosting expectations of

US STOCKS-Wall Street set for stronger open after inflation print; airlines slump on Delta forecast CPI data shows inflation eased in June PepsiCo dips on quarterly revenue miss Pfizer moves ahead with once-daily weight-loss pill, shares up Futures up: Dow 0.17%, S&P 500 0.22%, Nasdaq 0.28% Updated at 8:42 a.m. ET/1242 GMT By Lisa Pauline Mattackal and Ankika Biswas July 11 (Reuters) - Wall Street futures turned positive on Thursday after data showed inflation eased in June, boosting expectation

BUZZ-Pfizer's move to press ahead with weight-loss pill drags some drug developers Updates ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.3% to $55.50 premarket ** Pfizer PFE.N plans to advance a reworked, once-a-day version of its experimental obesity pill, danuglipron, to clinical trials in the second half of this year

BUZZ-U.S. STOCKS ON THE MOVE-Costco, PepsiCo, Alcoa Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. index futures slipped on Thursday on expectations that a key inflation print could shaperate-cuts bets and put Wall Street's record-breaking run to the test, while Delta Air Lines slumpedafter a weak forecast, dragging other airline stocks.

BUZZ-Pfizer's move to press ahead with weight-loss pill drags some developers Updates ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.8% to $55.22 premarket ** Pfizer PFE.N plans to advance a reworked, once-a-day version of its experimental obesity pill, danuglipron, to clinical trials in the second half of this year ** I

US STOCKS-Futures edge lower ahead of inflation test; Delta Airlines falls For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. CPI, weekly jobless claims data due at 8:30 a.m. ET PepsiCo dips on quarterly revenue miss Citigroup falls after US regulators slap $136-million fine Pfizer moves ahead with once-daily weight-loss pill, shares up Futures down: Dow 0.13%, S&P 500 0.11%, Nasdaq 0.08% Updated at 7:03 a.m.

BRIEF-Pfizer Advances Development Of Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron July 11 (Reuters) - Pfizer Inc PFE.N : PFIZER ADVANCES DEVELOPMENT OF ONCE-DAILY FORMULATION OF ORAL GLP-1 RECEPTOR AGONIST DANUGLIPRON PFIZER INC - ONGOING STUDY SHOWS FAVORABLE PHARMACOKINETIC PROFILE FOR DANUGLIPRON PFIZER INC - TO CONDUCT DOSE

BUZZ-Viking hit by Pfizer's plan for once-daily weight loss pill ** Shares of weight-loss drug developer Viking Therapeutics VKTX.O fall ~4.8% to $55.22 premarket ** Pfizer PFE.N says it will advance a reworked, once-a-day version of its experimental obesity pill, danuglipron to clinical trials in the second half of this year ** In March, VKTX said

BUZZ-Pfizer rises after moving forward with once-daily weight loss drug ** Shares of drugmaker Pfizer PFE.N rise 3.7% to $29.40 premarket ** Co says it will conduct studies in H2 2024 on a reworked, once-daily version of its experimental obesity pill, danuglipron ** PFE is testing the once-daily modified release dosing as well as a twice-daily form

UPDATE 4-Pfizer moves forward with once-daily weight-loss pill Adds details on timeframe in paragraph 4, analyst comment in paragraphs 7-8 By Michael Erman and Manas Mishra July 11 (Reuters) - Pfizer PFE.N plans to move a reworked, once -a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice- daily version of the drug late last year.

Pfizer moves forward with once-daily weight loss drug July 11 (Reuters) - Pfizer PFE.N said on Thursday it would conduct studies in the second-half of 2024 on a reworked, once-a-day version of its experimental obesity pill, danuglipron. The drugmaker last year said it was focusing on danuglipron's development after scrapping a separate, once-daily pill due to concerns about liver safety.

RPT-BRIEF-Evotec And Pfizer Collaborate To Advance Drug Discovery In France Repeats brief to connect to snaps, no changes to text July 10 (Reuters) - EVOTEC SE EVTG.DE : EVOTEC AND PFIZER COLLABORATE TO ADVANCE DRUG DISCOVERY IN FRANCE MULTI-YEAR COLLABORATION WILL INITIALLY FOCUS ON EARLY DISCOVERY RESEARCH FOR METABOLIC AND INFECTIOUS DISEASES AN

Column: SEC blasts Pfizer's bid for $75 million from insider trading victims' fund The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel July 9 (Reuters) - One of the most notorious insider trading schemes in U.S. history has led to a $75 million fight between drugmaker Pfizer and the U.S. Securities and Exchange Commission.

EXPLAINER-FLiRT COVID variants: What are they and are they more contagious? Adds details on KP.3 variant, U.S. vaccines By Michael Erman NEW YORK, July 9 (Reuters) - The so-called FLiRT variants of SARS-CoV-2 coronavirus that cause COVID-19 have been the dominant forms of the virus circulating this year globally, according to the World Health Organization FLiRT is an acronym for the locations of the mutations the variants share on the virus' spike protein.

UPDATE 2-Pfizer's chief scientist Mikael Dolsten to step down Adds background throughout, CEO quote in paragraph 5 July 9 (Reuters) - Pfizer PFE.N said on Tuesday Chief Scientific Officer Mikael Dolsten, a key figure behind the development of its COVID-19 vaccine, would step down after a more than 15-year career at the drugmaker. Dolsten, aged 65, served as the head of Pfizer's research and development after he joined the company through its $68 billion acquisition of Wyeth in 2009. He became th

Pfizer Chief Scientific Officer Mikael Dolsten to step down July 9 (Reuters) - Pfizer PFE.N said on Tuesday its chief scientific officer Mikael Dolsten would step down after more than 15 years with the drugmaker. Reporting by Christy Santhosh; Editing by Shilpi Majumdar

Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births By Christy Santhosh July 8 (Reuters) - Pfizer's PFE.N respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots. The vaccine Abrysvo was approved by the U.S.

UPDATE 4-Lilly beefs up bowel disease drug portfolio with $3.2 bln Morphic deal Updates share movement in paragraph 2 By Sriparna Roy July 8 (Reuters) - Eli Lilly LLY.N agreed to buy Morphic Holding MORF.O for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of inflammatory bowel disease (IBD) drugs and expanding its footprint in the multi-billion dollar market.